Financial reports from biotech's blue chip companies are coming thick and fast and so far none of them, filed during the past couple of days, appear to have harmed their market valuations despite the prevailing general market turbulence. Boston-based Vertex Pharmaceuticals Inc., for example, posted a significant 42 percent third-quarter jump in its total cystic fibrosis (CF) product revenues to $783 million, beating consensus by 2 percent. The company attributed the increase to a rapid uptake of its newest CF drug, Symdeko (tezacaftor/ivacaftor and ivacaftor), in the U.S., which recorded revenues of $255 million, up 37 percent over the previous quarter.